Nivolumab / Relatlimab (1) – Opdualag®
Melanoma, PD-L1 expression < 1 per cent, advanced, first-line treatment, ≥ 12 years
Characteristics
| Start date | 01.06.2026 |
|---|---|
| Resolution | 19.11.2026 – active procedure |
| INN | Nivolumab/Relatlimab |
| Brand name | Opdualag® |
| Pharm. company | Bristol-Myers Squibb GmbH & Co. KGaA |
| G-BA Procedure ID | D-1347 |
| Therapeutic area | Oncological diseases |
| Reason for procedure | Initial assessment |
Associated procedures
<< List of all resolutions